Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia 2019 (ICALL) /
Updates on bispecific T cell engagers (BiTEs) for the treatment of acute lymphoblastic leukaemia

17th - 19th May 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.05.19
Views: 1565
Rating:

Prof Max Topp - University of Würzburg, Würzburg, Germany

Prof Max Topp talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the latest developments in bispecific T cell therapy in acute lymphoblastic leukaemia (ALL).

He discusses the premise behind this therapy along with its clinical trial successes, including the approval of blinatumomab.

Prof Topp also acknowledges two main problems associated with this monotherapy which include the absence of CD19 in relapsed patients and in some cases a lack of response from patients. To improve this, Prof Topp mentions other B-cell antigens that can be targeted.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation